Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPAR δ Regulation in Hyperlipidemic and Hypertensive Conditions

Medicine & Life Sciences

• 11-beta-Hydroxysteroid Dehydrogenases 11%
• 3T3-L1 Cells 19%
• Acetyl-CoA Carboxylase 10%
• Acyl-CoA Dehydrogenase 12%
• Adenosine Monophosphate 8%
• Adiponectin 8%
• Biomarkers 5%
• Fatty Acid Synthases 10%
• Fatty Acids 13%
• Fatty Liver 8%
• fimasartan 91%
• GSK0660 15%
• Hep G2 Cells 8%
• High Fat Diet 7%
• Inbred SHR Rats 8%
• Intra-Abdominal Fat 17%
• Lipids 5%
• Lipoma 9%
• Liver 8%
• malonyl-CoA decarboxylase 14%
• Non-alcoholic Fatty Liver Disease 50%
• Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha 12%
• PPAR delta 71%
• Protein Kinases 7%
• Proteins 5%
• Tumor Necrosis Factor-alpha 5%

Chemical Compounds

• Acetyl-CoA 9%
• Acyl-CoA 10%
• Adenosine 7%
• Adiponectin 14%
• Antiadipogenic 14%
• Biological Marker 7%
• Delta Opiate Receptor Antagonist 13%
• Fat 15%
• Fatty Acid 19%
• Fimasartan 100%
• Hyperlipidemic 75%
• Hypertensive 65%
• Lipid 5%
• Malonyl-CoA 11%
• Pharmacological Metabolism 12%
• Protein 9%